Saturday, December 06, 2025 | 01:30 PM ISTहिंदी में पढें
Business Standard
Notification Icon
userprofile IconSearch

Is Ranbaxy an avoid given the US FDA extending the consent decree?

Click on to know Kunal Bothra's view, Technical Analyst at LKP Securities

Image

Jinsy Mathew Mumbai
Smartinvestor : What is your outlook on market and what are the key levels to watch out for on Nifty ?

Kunal Bothra : I think its a bit of a cautious approach for the markets, after yesterday's correction from day's high. I think that we could see a trading range for today as well. 5780 and 5850 are the key intraday levels to watch on Nifty spot levels.

Smartinvestor : What are your top picks from the banking names? And what are the levels?

Kunal Bothra : AXISBANK is forming a double top formation. I think below 1050 one could look at a trading opportunity of shorting for a target of 1020-1025 and stop loss at 1065.
 

Smartinvestor : Is Ranbaxy an avoid given the US FDA extending the consent decree? What do the charts suggest?

Click here for the full transcript


Don't miss the most important news and views of the day. Get them on our Telegram channel

First Published: Sep 17 2013 | 10:43 AM IST

Explore News